Key facts
- This page summarizes Brian Taylor Slingsby's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 20 Feb 2026, 19:47.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Other
Other
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Other
Other
Additional SEC filing notes
Footnote F1
Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
Footnote F2
Represents stock options or RSUs transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.
Footnote F3
Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Footnote F4
The stock option vests in 12 substantially equal monthly installments following the date of grant.